[at Barrons.com] – Gilead Sciences (GILD) delivered the goods last night when it reported its results. Today, however, the market is focused on the biotech companies forecast, which didn’t include projections for its new Hepatitis-C drug. Reuters has the details on Gilead’s earnings: Fourth-quarter net income rose 4 percent to $791.4 million from $762.5 million a year earlier. Adjusting for one-time items, the California-based company earned 55 cents a share, … [visit site to read more]
Similar Articles:- Market Update: Medtronic (NYSE:MDT), Bank of America (NYSE:BAC), Home Depot (NYSE:HD), Office Depot (NYSE:ODP)
- Story Stocks: 3M (NSYE:MMM), Johnson & Johnson (NYSE:JNJ), E.I. DuPont de Nemours (NYSE:DD), Monsanto (NYSE:MON)
- Market Update: Corning (NYSE: GLW), NetFlix (NASDAQ: NFLX), Verizon (NYSE: VZ), Microsoft (MSFT)